Marvel Biosciences Corp (TSE:MRVL) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Marvel Biosciences Corp. has announced encouraging interim findings for its drug candidate MB-204, showing its effectiveness in reducing Tau protein phosphorylation, which is linked to cognitive decline and various neurodegenerative diseases including Alzheimer’s. Conducted by Tau pathology expert Professor Emmanuel Planel, the study found that a low dose of MB-204 led to a significant reduction in Tau tangles in mice, a biomarker associated with disease progression and cognitive impairment. With the potential to address multiple neurological disorders, Marvel Biosciences is gearing up to begin clinical trials soon.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.